Last reviewed · How we verify
Docetaxel (DOC)
Docetaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in cancer cells.
Docetaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in cancer cells. Used for Metastatic breast cancer, Non-small cell lung cancer, Prostate cancer.
At a glance
| Generic name | Docetaxel (DOC) |
|---|---|
| Also known as | Docetaxel Injection |
| Sponsor | Sun Yat-sen University |
| Drug class | Taxane; microtubule stabilizer |
| Target | β-tubulin |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Docetaxel is a taxane that binds to the β-tubulin subunit of microtubules and prevents their disassembly, leading to stabilization of the microtubule structure. This disrupts normal cell division by blocking cells in the G2/M phase of the cell cycle, ultimately triggering apoptosis in rapidly dividing cancer cells. It is effective against a broad range of solid tumors.
Approved indications
- Metastatic breast cancer
- Non-small cell lung cancer
- Prostate cancer
- Gastric cancer
- Head and neck cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Peripheral neuropathy
- Alopecia
- Nausea and vomiting
- Diarrhea
- Mucositis
- Hypersensitivity reactions
Key clinical trials
- NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer (PHASE2)
- Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC) (PHASE3)
- Evaluation of the Efficacy of Darolutamide Triplet Therapy in Patients With Metastatic Hormone-sensitive Prostate Cancer
- Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder (PHASE1, PHASE2)
- Neoadjuvant Immunochemotherapy for Adenocarcinoma of the Esophagogastric Junction (PHASE2)
- Multicentric Randomised Trial for Resectable Gastric Cancer (PHASE2)
- Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer (PHASE2)
- ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Docetaxel (DOC) CI brief — competitive landscape report
- Docetaxel (DOC) updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI